Low-dose oral minoxidil in children: an international consensus on who, how much and what to watch

Design

International modified Delphi consensus, three rounds

Population

49 experienced clinicians from 9 countries

Primary outcome

Agreement of 70% or more on 127 statements

Effect

84 statements reached consensus, including indications, dosing and contraindications

A modified Delphi process, run from mid-2025 to March 2026, gathered 49 experienced clinicians from nine countries, each of whom had treated more than ten children with low-dose oral minoxidil. Agreement of 70% or more defined consensus, and 84 of 127 statements reached it.

The panel supported its use in children aged 4 to under 12 for hair follicle miniaturisation and hair cycle disorders (100% agreement), hair shaft disorders (84%), and as an adjunct in selected scarring alopecias. Reasons to prefer it over topical minoxidil included poor tolerability, difficulty applying it, inadequate response, diffuse loss, sensory sensitivities and risk to household pets. Suggested starting doses were weight-based (under 20 kg, 0.25-0.625 mg; 20-40 kg, 1.25 mg; over 40 kg, 1.875 mg) or 0.01-0.02 mg/kg/day, with escalation by 50-100% and review every 3-6 months. Pericardial effusion or tamponade and phaeochromocytoma were contraindications. The experts did not consider routine baseline tests or blood pressure monitoring necessary for low-risk children.

This is expert opinion, not trial evidence, and the drug remains off-label in children. Its value is in standardising dosing for clinicians already prescribing it. In India, low-strength tablets may not be available and splitting larger tablets can make small doses inaccurate.

• Consider low-dose oral minoxidil for children aged 4 to under 12 with non-scarring hair loss when topical minoxidil is impractical or has failed.
• Start at 0.01-0.02 mg/kg/day, or the panel's weight-band dose, and review every 3-6 months.
• Ask about cardiac history and exclude pericardial effusion and phaeochromocytoma before starting.
• Warn families about increased body hair, the most common side effect.
• Document off-label use and the discussion with parents.

Why it matters

Clinicians already prescribe it in children; this gives them shared starting doses and contraindications instead of improvising.

Don't overread it

A consensus statement records expert agreement; it is not evidence of efficacy or safety from trials in children.

The statistics, in plain English

The percentages here are levels of agreement among experts, not response rates in patients. A statement reaching 100% agreement is a strong shared view, but it can still be wrong without trial data to test it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.